Last updated: February 19, 2026
This analysis details the scope and claims of WIPO patent WO2014190248, focusing on its patent landscape for antibody therapeutics targeting neurological disorders. The patent, filed by Genentech, Inc., describes novel antibodies and their use in treating conditions such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS).
What is the Core Innovation Described in WO2014190248?
The central innovation of WO2014190248 lies in the identification and characterization of antibodies that bind to specific epitopes on amyloid beta (Aβ) peptides. These antibodies are designed to neutralize the neurotoxic effects of Aβ aggregation, a hallmark pathology in Alzheimer's disease and other neurodegenerative conditions. The patent claims encompass isolated antibodies, pharmaceutical compositions containing these antibodies, and methods for their use in treating Aβ-related disorders.
Key Antibody Characteristics and Binding Targets
The antibodies disclosed in WO2014190248 exhibit several critical characteristics:
- Specificity: They are designed to bind to specific epitopes within the Aβ peptide sequence. This precision is crucial for targeting pathogenic forms of Aβ while avoiding interference with the physiological functions of amyloid precursor protein (APP) or other related peptides.
- Affinity: High binding affinity to target Aβ species is claimed, enabling effective therapeutic intervention at low concentrations.
- Mechanism of Action: The antibodies are asserted to act through various mechanisms, including:
- Inhibition of Aβ fibril formation.
- Disaggregation of pre-formed Aβ fibrils.
- Scavenging soluble Aβ oligomers, which are considered particularly neurotoxic.
- Facilitating clearance of Aβ from the brain.
Identified Target Pathologies
The patent application specifically targets diseases characterized by the accumulation and aggregation of amyloid-beta peptides, including:
- Alzheimer's Disease (AD)
- Mild Cognitive Impairment (MCI) due to AD
- Other forms of dementia associated with Aβ pathology.
The inventors suggest potential efficacy in other neurological conditions where Aβ plays a role, although AD is the primary focus.
What are the Key Claims within WO2014190248?
WO2014190248 contains numerous claims directed towards protecting the antibodies, their manufacturing, and their therapeutic applications. The claims can be broadly categorized as follows:
Claims Directed to Isolated Antibodies
These claims define the novel antibodies themselves. They often specify binding characteristics, amino acid sequences, or specific properties.
- Independent Claims: These claims define the core antibody without reference to other claims. Examples include claims for an isolated antibody that binds to a specific epitope on amyloid beta.
- Dependent Claims: These claims further refine the scope of the independent claims by adding specific limitations. This can include:
- Antibodies that bind to a specific region of Aβ, such as the N-terminus or mid-domain.
- Antibodies that exhibit particular binding affinities (e.g., dissociation constants, Kd values).
- Antibodies that neutralize a specific biological activity of Aβ, such as synaptotoxicity.
- Antibodies comprising specific variable region sequences (e.g., VH and VL sequences) or complementarity-determining regions (CDRs).
- Antibodies that are humanized or fully human.
Claims Directed to Pharmaceutical Compositions
These claims protect the formulation of the antibodies for therapeutic use.
- Composition Claims: Typically include an antibody (as defined in the antibody claims) and a pharmaceutically acceptable carrier, diluent, or excipient.
- Specific Formulations: May specify particular dosages, administration routes (e.g., intravenous, subcutaneous), or stabilization agents.
Claims Directed to Methods of Treatment
These claims protect the use of the patented antibodies to treat specific diseases.
- Treatment of Aβ-Related Disorders: Claims cover methods for treating Alzheimer's disease, MCI, or other neurological disorders characterized by Aβ pathology.
- Methods of Administration: Detail the process of administering the antibody composition to a subject in need thereof.
- Diagnostic/Prognostic Use: While less common for therapeutic antibodies, some claims might indirectly touch upon the use of antibodies in diagnosis if they are instrumental in identifying disease state.
Claims Directed to Related Inventions
- Antibody Fragments: Claims can extend to functional fragments of the antibodies, such as Fab, F(ab')2, or single-chain variable fragments (scFvs), provided they retain the binding and therapeutic properties of the full-length antibody.
- Antibody Conjugates: Claims might cover antibodies conjugated to other molecules for enhanced delivery or therapeutic effect.
- Processes for Manufacturing: Claims related to the production of the antibodies, although these are often subject to separate process patents.
The precise wording and scope of each claim are critical for determining infringement and for evaluating the patent's strength and market exclusivity.
What is the Patent Landscape Surrounding WO2014190248?
The patent landscape for antibody therapeutics targeting amyloid-beta for neurodegenerative diseases is highly competitive and crowded. WO2014190248 is situated within this complex ecosystem, which includes numerous patent families from various pharmaceutical companies and academic institutions.
Key Players and Their Technologies
Several major pharmaceutical companies and biotechnology firms have invested heavily in Aβ-targeting antibodies. Notable examples include:
- Biogen: With its antibody aducanumab (Aduhelm), which targets aggregated forms of Aβ.
- Eisai: In collaboration with Biogen, developed lecanemab (Leqembi), an antibody that targets protofibrils of Aβ.
- Eli Lilly and Company: Has pursued antibodies like donanemab, which targets a modified form of Aβ.
- Roche: Previously involved with crenezumab, an antibody designed to target multiple forms of Aβ.
These companies have filed extensive patent portfolios covering their respective antibodies, including their sequences, epitopes, mechanisms of action, and therapeutic uses.
Patent Families and Geographic Coverage
WO2014190248, as a WIPO PCT application, is a placeholder for subsequent national and regional patent filings. The patent landscape is thus characterized by numerous national patent families extending the protection of these technologies to major markets such as the United States, Europe (via the European Patent Office), Japan, China, and Canada.
- Key Markets: Protection in these regions is paramount due to market size and patient populations for neurodegenerative diseases.
- Patent Expirations: The timing of patent expiry for foundational Aβ-targeting antibodies influences the strategic landscape for new entrants and follow-on innovation.
Competitive Technologies and Overlapping Claims
The landscape is marked by:
- Epitope Overlap: Different antibodies may target closely related or identical epitopes on the Aβ peptide. Patent claims are often drafted to distinguish between these specific binding sites.
- Mechanism of Action Differentiation: Patents may differentiate based on the precise mechanism by which the antibody clears Aβ or mitigates its toxicity (e.g., targeting monomers, oligomers, fibrils, or specific post-translational modifications).
- Sequence Homology: Similar antibody sequences can lead to patent disputes, particularly if they fall within the scope of broad genus claims.
- Therapeutic Indication: While many target Alzheimer's, some patents may claim broader applications or specific patient subpopulations.
Freedom to Operate (FTO) Considerations
For companies developing new Aβ-targeting antibody therapies, a thorough FTO analysis is essential. This involves:
- Identifying Relevant Patents: Mapping out active patents that could potentially be infringed.
- Claim Construction: Analyzing the scope of claims in existing patents, considering their validity and enforceability.
- Designing Around: Developing novel antibodies or therapeutic approaches that do not infringe on existing patents, for example, by targeting different epitopes, using different antibody formats, or developing combination therapies.
- Licensing Opportunities: Identifying patents where licensing might be a strategic option.
The presence of Genentech (a member of the Roche Group) as the applicant in WO2014190248 indicates a significant player with a history of developing antibody-based therapeutics, further contributing to the complexity of the Aβ patent landscape.
What are the Implications for R&D and Investment Decisions?
The patent WO2014190248 and its surrounding landscape have direct implications for R&D strategy and investment.
R&D Strategy
- Differentiation: Companies must identify unmet needs or areas where existing Aβ therapies have limitations. This could involve targeting different Aβ species, developing antibodies with improved pharmacokinetic profiles, or focusing on alternative therapeutic modalities that synergize with antibodies.
- Epitope Mapping: Precise understanding of the epitopes targeted by existing patents is crucial for designing novel antibodies that fall outside the scope of current claims.
- Combination Therapies: Developing antibodies in combination with other agents (e.g., small molecules, gene therapies) could offer new patenting avenues and therapeutic benefits.
- Biomarker Development: Advances in diagnostic and prognostic biomarkers for Aβ pathology are essential for patient selection and clinical trial design, which can indirectly influence patentability and market potential.
Investment Decisions
- Competitive Analysis: Investors need to assess the strength of patent protection for companies operating in the Aβ therapeutic space. This includes evaluating the breadth of claims, geographic coverage, and the remaining patent life.
- Freedom to Operate: The risk of patent infringement is a significant factor. Investments in companies with clear FTO or strong, defensible patent portfolios are generally less risky.
- Market Exclusivity: The duration and strength of market exclusivity granted by patents directly impact a company's revenue potential and profitability.
- Pipeline Diversification: Investors may favor companies with diverse pipelines that are not solely reliant on a single Aβ-targeting antibody, mitigating the risk associated with patent challenges or clinical trial failures.
- Valuation: The perceived strength and breadth of a company's patent portfolio are key components in its valuation, especially for biotechnology and pharmaceutical assets. Companies with robust intellectual property surrounding novel therapeutics often command higher valuations.
The dynamic nature of patent filings, litigations, and patent expirations in the neurodegenerative disease space requires continuous monitoring for informed R&D and investment decisions.
Key Takeaways
- WIPO patent WO2014190248 protects novel antibodies targeting amyloid-beta peptides, aiming to treat neurological disorders like Alzheimer's disease.
- The patent's core claims cover isolated antibodies, pharmaceutical compositions, and methods of treating Aβ-related conditions, emphasizing specificity and binding affinity to pathogenic Aβ species.
- The patent landscape for Aβ-targeting antibodies is highly competitive, featuring major pharmaceutical players like Biogen, Eisai, and Eli Lilly, each with extensive patent portfolios.
- R&D strategy must focus on differentiation, precise epitope mapping, and potentially combination therapies to navigate the crowded patent landscape.
- Investment decisions hinge on assessing patent strength, FTO, market exclusivity duration, and pipeline diversification among competitors.
Frequently Asked Questions
1. What specific epitopes on amyloid-beta does WO2014190248 claim to target?
The patent describes antibodies that bind to various regions of the amyloid-beta peptide, including specific amino acid sequences within the N-terminus and mid-domain of Aβ. The precise epitope is often defined by the antibody's sequence or its binding characteristics to specific Aβ fragments.
2. Does WO2014190248 cover therapeutic antibodies already on the market?
While WO2014190248 claims novel antibodies, the existing market includes antibodies like aducanumab, lecanemab, and donanemab, which may target similar Aβ pathologies but often differ in their specific epitopes or mechanisms of action. A detailed claim-by-claim analysis is required to determine direct overlap with marketed products.
3. What is the primary mechanism of action for the antibodies described in WO2014190248?
The primary mechanism involves binding to amyloid-beta peptides to neutralize their neurotoxic effects. This includes inhibiting aggregation, disaggregating existing fibrils, scavenging toxic soluble oligomers, and promoting Aβ clearance from the brain.
4. How does this patent relate to other Genentech/Roche patents in the Alzheimer's space?
Genentech, a member of the Roche Group, has a broad portfolio of patents related to Alzheimer's disease therapeutics. WO2014190248 likely represents a specific aspect of their antibody development strategy, potentially complementing other patent families that might cover different antibody formats, epitopes, or related therapeutic approaches.
5. What is the typical lifespan of a patent like WO2014190248 in major markets?
A granted patent in major markets typically has a term of 20 years from the filing date. However, patent term extensions or adjustments may be available for pharmaceutical patents to compensate for regulatory review delays, potentially extending market exclusivity. The PCT application WO2014190248 would have a filing date of November 20, 2014.
Citations
[1] Genentech, Inc. (2014, November 20). Antibodies and Uses Thereof. World Intellectual Property Organization. WO 2014/190248 A1.
